Obesity Medicine最新文献

{"title":"The emerging role of epsilon cells in glucose homeostasis and lipostasis","authors":"N. Pavithra ,&nbsp;S. Ankul Singh ,&nbsp;Rukaiah Fatma Begum ,&nbsp;Krishna Undela ,&nbsp;S. Nirenjen ,&nbsp;B. Keerthana ,&nbsp;Anuragh Singh ,&nbsp;R. Mageswari ,&nbsp;Sarvesh Sabarathinam","doi":"10.1016/j.obmed.2025.100672","DOIUrl":"10.1016/j.obmed.2025.100672","url":null,"abstract":"<div><div>Epsilon (ε) cells represent the rarest endocrine population within the pancreatic islets but serve as the exclusive intra-islet source of ghrelin, a hormone increasingly recognized as a regulator of glucose homeostasis, β-cell function, and lipid metabolism. Once considered primarily an orexigenic signal, ghrelin is now understood to influence intra-islet crosstalk through direct β-cell inhibition and indirect somatostatin-mediated suppression of insulin secretion. Advances in single-cell and multi-omic technologies have refined the molecular identity of ε-cells, uncovering PDX1-low, NKX6.1-negative ghrelin-lineage signatures and non-coding RNA networks that stabilize their fate. ε-cell number and ghrelin output change dynamically across fetal development, adulthood, aging, and metabolic disease. In type 1 diabetes, ε-cell dysfunction occurs against a backdrop of autoimmune β-cell destruction, whereas in type 2 diabetes, impaired ghrelin signaling contributes directly to β-cell failure and metabolic deterioration. Obesity presents a paradox of suppressed circulating ghrelin yet preserved intra-islet activity, mediated partly by the LEAP2–GHSR1a axis. These insights highlight ε-cells as modulators of glucose and energy balance and identify ghrelin-axis interventions, including GHSR antagonists, GOAT inhibitors, and LEAP2 analogs, as emerging therapeutic strategies. This review synthesizes current knowledge on ε-cell biology, their context-dependent roles in diabetes and obesity, and future directions for targeting ε-cell pathways to improve metabolic health.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100672"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Frontiers in diabetic foot ulcers: Bridging science and clinical practice","authors":"Palwinder Kaur ,&nbsp;Amani Gilbert Mfinanga ,&nbsp;Vancha Harish ,&nbsp;Sharfuddin Mohd ,&nbsp;J.P. Yanadaiah ,&nbsp;Palakurthi Yanadaiah ,&nbsp;Krishnaveni Manubolu","doi":"10.1016/j.obmed.2025.100678","DOIUrl":"10.1016/j.obmed.2025.100678","url":null,"abstract":"<div><div>Diabetic foot ulcers (DFUs) are one of the serious complications of diabetes mellitus, contributing to lower limb amputations and leading to decreased quality of life (QoL). Despite many advancements in the pathological approach of DFU, including neuropathy, ischemia, infection, and impaired wound healing, translating scientific breakthroughs into a clinical setup is still a major challenge. This review highlights current advancements in DFU management by bridging the gap between scientific innovations and clinical applications. It focuses on the role of emerging therapies, such as stem cell therapies, 3D bioprinting, and nanotechnology applications. 3D printing customised wound coverings, such as Manipulated Autologous Extracellular Matrix (MA-ECM), demonstrated accelerated wound recovery compared to standard of care. In addition, the review highlights integrative approaches such as negative-pressure wound therapy, hyperbaric oxygen therapy, and diagnostic advancements enabled by artificial intelligence tools. The review explores the antimicrobial and biofilm targeting by using silver nanoparticles, bacteriophages, and photodynamic and blue light therapies. The review further describes the role of AI and ML in wound assessment, and the role of biophysical and electro-magnetic therapies in management.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100678"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and associated factors of obesity, diabetes, and hypertension among university students in Jordan","authors":"Mohammad Bani Younis ,&nbsp;Mais Bani Younis","doi":"10.1016/j.obmed.2025.100663","DOIUrl":"10.1016/j.obmed.2025.100663","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus is a chronic metabolic disorder with increasing global prevalence, particularly linked to obesity. Obesity, measured by Body Mass Index, significantly heightens the risk of type 2 diabetes, with Arab countries showing some of the highest diabetes rates. Hypertension, another prevalent non-communicable disease, also poses significant cardiovascular risks, with early onset during adolescence and a growing burden worldwide.</div></div><div><h3>Aims</h3><div>This research aims to investigate the prevalence of diabetes, hypertension, and obesity among university students. Another aim is to investigate the factors associated with diabetes and hypertension among university students.</div></div><div><h3>Results</h3><div>The blood pressure analysis shows 66 % of participants with normal levels, while 18 % have elevated and 16 % are hypertensive. Average systolic and diastolic pressures were 118.87 mmHg and 70.79 mmHg, respectively. Blood glucose measurements revealed variability, with fasting levels averaging 87.15 mg/dL and random levels averaging 95.12 mg/dL. Approximately 8 % of participants were prediabetic and 5 % were diabetic. The body mass index (BMI) values ranged from 16.87 to 45.70, with 59 % of participants in the normal range, 25 % classified as overweight, and 13 % as obese. Cluster analysis reveals that 63 % of the students had no cardiometabolic risk condition, 28 % had one condition, and 9 % had a clustering of more than one condition. Binary logistic regression indicates that each one-unit increase in BMI was associated with an 83 % higher likelihood of having high FBS. The results of the chi-square analysis suggest that individuals with obesity may have a substantially higher likelihood of hypertension and diabetes mellitus.</div></div><div><h3>Conclusion</h3><div>The study highlights a concerning prevalence of hypertension and obesity among university students, with 16 % classified as hypertensive and 13 % as obese. Although the majority of participants maintained normal blood pressure and BMI levels, the elevated rates of hypertension and obesity suggest an increased risk for future cardiovascular and metabolic disorders.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100663"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut Microbiota–Leptin crosstalk in obesity and metabolic dysregulation","authors":"Loushambam Samananda Singh ,&nbsp;Laimayum Amarnath Sharma","doi":"10.1016/j.obmed.2025.100671","DOIUrl":"10.1016/j.obmed.2025.100671","url":null,"abstract":"<div><div>The gut microbiota has emerged as a fundamental regulator of host metabolic processes, significantly influencing energy balance, inflammatory responses, and endocrine signaling. Leptin, a key hormonal mediator of energy homeostasis, is secreted by adipocytes and regulates appetite, thermogenesis, and lipid metabolism via central and peripheral mechanisms. Dysregulation of leptin signaling, characterized by hyperleptinemia and leptin resistance, is a hallmark of obesity and related metabolic disorders, such as insulin resistance, type 2 diabetes, and non-alcoholic fatty liver disease. Gut microbiota-derived modulators, including short-chain fatty acids (SCFAs), lipopolysaccharides (LPS), bile acids, and other microbial metabolites, significantly affect leptin expression, secretion, and its downstream signaling. These microbial signals interact with intestinal and systemic immune pathways, alter gut permeability, and influence neuroendocrine axes, collectively shaping leptin sensitivity and affecting metabolic outcomes. Gut dysbiosis has been linked to impaired leptin transport across the blood–brain barrier and disrupted hypothalamic signaling, further exacerbating metabolic dysfunction. Leptin may influence the gut microbial composition, highlighting a bidirectional regulatory relationship. This review synthesizes the current evidence on gut microbiota–leptin crosstalk and explores emerging microbiota-targeted strategies to restore leptin sensitivity, offering promising avenues for managing obesity and its associated metabolic complications.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100671"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D deficiency in obesity: Epidemiological evidence, biological mechanisms, and clinical considerations","authors":"Reem J. Al Argan ,&nbsp;Safi G. Alqatari ,&nbsp;Abrar J. Alwaheed ,&nbsp;Manal A. Hasan ,&nbsp;Shaya Y. AlQahtani ,&nbsp;Mohammed D. Al Shubbar ,&nbsp;Abdullah H. Alnasser ,&nbsp;Safia M. Al Abbas ,&nbsp;Noor H. AlYousef","doi":"10.1016/j.obmed.2025.100680","DOIUrl":"10.1016/j.obmed.2025.100680","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Obesity is a global public health crisis, contributing to substantial morbidity and mortality due to its strong association with chronic diseases such as type 2 diabetes, cardiovascular disorders, and malignancies. Concurrently, vitamin D deficiency has become widespread, affecting nearly one billion people worldwide. Epidemiological studies consistently demonstrate an inverse relationship between obesity and vitamin D levels, with emerging hypotheses suggesting a bidirectional link.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This review examines the association between obesity and vitamin D status, the underlying biological mechanisms, the role of vitamin D in metabolic disease, and the implications of vitamin D supplementation in obese populations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Epidemiological studies confirm that obese individuals exhibit significantly lower circulating 25-hydroxyvitamin D [25(OH)D] levels than their normal-weight counterparts. Mendelian randomization analyses further establish a causal link, indicating that obesity leads to vitamin D deficiency, rather than vice versa. Proposed biological mechanisms include volumetric dilution due to increased adipose tissue, sequestration of vitamin D in fat stores, and obesity-related impairments in vitamin D metabolism. Vitamin D plays a crucial role in metabolic health by influencing insulin secretion, lipid metabolism, and blood pressure regulation. Deficiency has been associated with insulin resistance, dyslipidemia, and overactivation of the renin-angiotensin-aldosterone system (RAAS), exacerbating obesity-related metabolic complications. However, while vitamin D supplementation effectively raises serum 25(OH)D levels, its impact on improving metabolic outcomes remains inconsistent across interventional studies. In addition, the joint impact of obesity and vitamin D deficiency on bone health remains unexplored, despite distinct mechanisms suggesting additive or synergistic harm. Targeted studies are needed to assess their combined effects using robust designs and comprehensive skeletal outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The strong inverse relationship between obesity and vitamin D status highlights the need for targeted interventions. While weight loss modestly improves vitamin D levels, BMI-adjusted vitamin D supplementation may be the most effective strategy for correcting deficiency in obese populations. Current guidelines suggest that obese individuals require higher doses of vitamin D to achieve optimal serum levels. However, further research is necessary to refine dosing strategies and determine the long-term impact of supplementation on metabolic health outcomes. Future investigations should integrate personalized supplementation approaches with lifestyle and pharmacological interventions to mitigate obesity-related metabolic disturbances effectively. Furthermore, obesity and vitamin D deficiency may jointly exacerbate skeletal de","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100680"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional knowledge and obesity in healthcare vs. non-healthcare hospital personnel","authors":"Sanja Lepić ,&nbsp;Sonja Marjanović","doi":"10.1016/j.obmed.2025.100676","DOIUrl":"10.1016/j.obmed.2025.100676","url":null,"abstract":"<div><h3>Objective</h3><div>Healthcare personnel are pivotal in promoting healthy lifestyles, including balanced nutrition. This study compares nutritional knowledge and its relationship with anthropometric measures between healthcare and non-healthcare personnel at a tertiary healthcare facility.</div></div><div><h3>Methods</h3><div>A cross-sectional study of 200 participants (100 healthcare, 100 non-healthcare personnel; equal gender distribution) used questionnaires to assess nutritional knowledge across four domains and measured anthropometric indices (BMI, PBF). Statistical analyses included t-tests, chi-square tests, and ANOVA.</div></div><div><h3>Results</h3><div>Healthcare personnel demonstrated significantly better nutritional knowledge (p &lt; 0.01) and health awareness (p &lt; 0.05) than non-healthcare personnel. Females scored higher in dietary habits (p = 0.03) and health awareness (p = 0.04). While no direct correlation between total nutrition scores and BMI/PBF was found, higher physical activity scores were linked to healthier anthropometric measures (p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Enhanced nutritional knowledge among healthcare personnel, particularly women, may influence healthier body composition. This study highlights the need to address nutritional knowledge gaps and promote healthier lifestyles. Further research should explore targeted interventions for knowledge application in obesity prevention.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100676"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor regarding the article “Exploring uric acid as a biomarker in lipedema and lymphedema: A metabolomics study with prospective validation”","authors":"S. Arin Natania","doi":"10.1016/j.obmed.2025.100666","DOIUrl":"10.1016/j.obmed.2025.100666","url":null,"abstract":"<div><div>I found the recent study by Alkhalfan et al. for identifying uric acid as a potential biomarker for lipedema and lymphedema through untargeted plasma metabolomics. To further enhance the clinical translation of these findings, I, propose a structured framework comprising baseline control characterization, longitudinal uric acid profiling across treatment phases, multi-analyte biomarker integration, and endocrine-based stratification. This approach aims to improve diagnostic specificity, accommodate inter-individual variability, and establish uric acid as a reliable tool in differentiating and monitoring lymphatic disorders.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100666"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment approaches for co-occurring hypothyroidism and obesity: A systematic literature review","authors":"Harini K N ,&nbsp;Savithri Nilkantham","doi":"10.1016/j.obmed.2025.100665","DOIUrl":"10.1016/j.obmed.2025.100665","url":null,"abstract":"<div><h3>Objective</h3><div>The co-occurrence of hypothyroidism and obesity has drawn growing research attention due to their shared metabolic and hormonal links, which collectively worsen health outcomes and quality of life. This study evaluates current treatment strategies and examines the potential of integrative approaches to treat individuals experiencing both conditions.</div></div><div><h3>Design/methodology/approach</h3><div>This systematic review examines clinical studies on treatments for co-occurring hypothyroidism and obesity. A comprehensive search was carried out in Scopus and Web of Science databases using 12 different search terms till September 2025 in the area of “hypothyroidism and obesity treatments” following PRISMA guidelines to select the relevant English-language peer-reviewed articles for review.</div></div><div><h3>Principle findings</h3><div>This study categorizes treatment approaches for co-occurring hypothyroidism and obesity into two primary groups: “Conventional and Non-conventional”, with each comprising distinct sub-groups. Conventional treatments include medication (oral or injectable drugs) and surgery (such as laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, or thyroidectomy); non-conventional treatments encompass lifestyle (diet, nutrition, exercise, and micronutrient supplementation) and complementary therapies (yoga, Ayurveda, naturopathy, and other mind–body practices). The findings highlight the need for further research on non-conventional treatments for subclinical forms of hypothyroidism and obesity and also combining conventional &amp; non-conventional approaches for managing clinical hypothyroidism and obesity.</div></div><div><h3>Conclusion</h3><div>Hypothyroidism and obesity often co-occur, complicating treatment. While conventional treatments like medication and surgery target thyroid function, non-conventional treatments like lifestyle and complementary therapy, improve metabolism, stress management, and well-being. To the best of our knowledge, this is the first systematic literature review that evaluates several treatment methods for the combined adverse effects of hypothyroidism and obesity, suggesting effective control and prevention strategies and proposing directions for future research.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100665"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing post-bariatric surgery weight management: The role of semaglutide","authors":"Tannaz Jamialahmadi ,&nbsp;Wael Almahmeed ,&nbsp;Salim S. Virani ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.obmed.2025.100675","DOIUrl":"10.1016/j.obmed.2025.100675","url":null,"abstract":"","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100675"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The underestimated axis: Enteroendocrine-Microbiota interactions in obesity pathogenesis and therapy","authors":"S Arin Natania","doi":"10.1016/j.obmed.2025.100668","DOIUrl":"10.1016/j.obmed.2025.100668","url":null,"abstract":"","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"59 ","pages":"Article 100668"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}